Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626782 · ClinicalTrials.gov registry record · Phase 2
Lucentis Versus Mitomycin C During Glaucoma Surgery
A Phase 2 study of Glaucoma, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00626782: Completed Phase 2 study of Glaucoma, sponsored by Wills Eye.
NCT00626782 is a Phase 2 study of Glaucoma that has completed, run by Wills Eye. The registered enrollment target is 24 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00626782, a Phase 2 study of Glaucoma, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.
Primary Outcome
Percentage of participants with ocular adverse events and other adverse events as identified by eye examination, physical examination, subject reporting and changes in vital signs one year post-operatively.
Conditions Studied
Interventions
- DRUG Ranibizumab
- DRUG Mitomycin (MMC)
Study Locations (1)
Pennsylvania
- Wills Eye Hospital, Glaucoma Service - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
What the finished NCT00626782 record still lists
NCT00626782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT00626782 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00626782 about?
NCT00626782 is a clinical study titled "Lucentis Versus Mitomycin C During Glaucoma Surgery". Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and inf...
What is the current status of trial NCT00626782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-01. Estimated completion is 2011-04.
What conditions does trial NCT00626782 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00626782?
The interventions under investigation include: Ranibizumab (DRUG), Mitomycin (MMC) (DRUG).
Who is sponsoring clinical trial NCT00626782?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626782 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00626782's enrollment target sits among peer trials
24 84th of 92 higher than 9 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia